Search Results - "Poveda Andrés, Jose Luis"

Refine Results
  1. 1

    Impact of voriconazole plasma concentrations on treatment response in critically ill patients by Ruiz, Jesus, Gordon, Mónica, Villarreal, Esther, Peruccioni, Marcela, Marqués, María Remedios, PovedaAndrés, Jose Luis, Castellanos‐Ortega, Álvaro, Ramirez, Paula

    “…Summary What is known and objective Several authors have demonstrated the relationship between voriconazole concentrations and the risk of therapeutic failure…”
    Get full text
    Journal Article
  2. 2

    Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report by Fernández‐Sánchez, Mireya, Ribes‐Artero, Hugo, Romá‐Sánchez, Eva, Gómez‐Portero, M. Rosa, Guerrero‐Hurtado, Eduardo, García‐Pellicer, Javier, PovedaAndrés, Jose Luis

    Published in Birth defects research (15-10-2021)
    “…Introduction Preclinical studies with tofacitinib demonstrated teratogenic effects. Data about effects on human fetuses are limited and current recommendations…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection by Solé, Amparo, García‐Robles, Ana A., Jordá, Carlos, Cases Viedma, Enrique, Mancheño, Nuria, PovedaAndrés, José Luis, Reig Mezquida, Juan Pablo, Pemán, Javier

    Published in American journal of transplantation (01-02-2018)
    “…Scedosporium is an important pathogen in cystic fibrosis (CF) and post‐transplantation, but it rarely causes invasive infection. Treatment remains challenging,…”
    Get full text
    Journal Article
  5. 5

    Drug Interaction Between Oral Cyclosporine Modified and Iron by Domingo-Chiva, Esther, Ruíz-Ramos, Jesús, Marqués-Miñana, Maria-Remedios, Valladolid-Walsh, Ana, Poveda-Andrés, Jose-Luis

    Published in The Annals of pharmacotherapy (01-07-2014)
    “…Objective: To describe a recent case of suspected interaction between oral cyclosporine modified and iron. Case Summary: A 33-year-old man underwent urgent…”
    Get full text
    Journal Article
  6. 6

    Pharmacometabolomics by NMR in Oncology: A Systematic Review by Gómez-Cebrián, Nuria, Vázquez Ferreiro, Pedro, Carrera Hueso, Francisco Javier, Poveda Andrés, José Luis, Puchades-Carrasco, Leonor, Pineda-Lucena, Antonio

    Published in Pharmaceuticals (Basel, Switzerland) (02-10-2021)
    “…Pharmacometabolomics (PMx) studies aim to predict individual differences in treatment response and in the development of adverse effects associated with…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart ® in patients with multiple sclerosis by Edo Solsona, María Dolores, Monte Boquet, Emilio, Casanova Estruch, Bonaventura, Poveda Andrés, José Luis

    Published in Patient preference and adherence (01-01-2017)
    “…Adherence to disease-modifying drugs (DMDs) is one of the key factors for achieving optimal clinical outcomes. Rebismart is an injection device for…”
    Get full text
    Journal Article
  9. 9

    Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes by Gómez-Cebrián, Nuria, Gras-Colomer, Elena, Poveda Andrés, José Luis, Pineda-Lucena, Antonio, Puchades-Carrasco, Leonor

    Published in Biology (Basel, Switzerland) (23-08-2023)
    “…Lysosomal storage disorders (LSDs) constitute a large group of rare, multisystemic, inherited disorders of metabolism, characterized by defects in lysosomal…”
    Get full text
    Journal Article
  10. 10

    Analysis of chemical contamination by hazardous drugs with BD HD Check® system in a tertiary hospital by Valero García, Silvia, Centelles-Oria, María, Palanques-Pastor, Tomás, Vila Clérigues, Nieves, López-Briz, Eduardo, Poveda Andrés, José Luis

    Published in Journal of oncology pharmacy practice (01-10-2022)
    “…The presence of contamination in the healthcare work environment by one of the types of hazardous drugs, cytostatics, has been found in multiple international…”
    Get full text
    Journal Article
  11. 11
  12. 12
  13. 13

    Reduction in alert fatigue in an assisted electronic prescribing system, through the Lean Six Sigma methodology by Monreal, M.a Jesús Cuéllar, Aguado, Jorge Reig, Noguera, Isabel Font, Andrés, José Luis Poveda

    Published in Farmacia hospitalaria (01-01-2017)
    “…To reduce the alert fatigue in our Assisted Electronic Prescribing System (AEPS), through the Lean Six Sigma (LSS) methodology. An observational (transversal)…”
    Get full text
    Journal Article
  14. 14
  15. 15
  16. 16

    Impact of an antimicrobial stewardship program on critical haematological patients by Ruiz-Ramos, Jesús, Frasquet, Juan, Poveda-Andrés, José Luis, Romá, Eva, Salavert-Lleti, Miguel, Castellanos, Álvaro, Ramírez, Paula

    Published in Farmacia hospitalaria (01-07-2017)
    “…Antimicrobial Stewardship Programs (ASPs) have appeared as very useful tools in order to improve the use of antimicrobial agents. The objective of this study…”
    Get full text
    Journal Article
  17. 17

    Hazardous drugs: new challenges, new opportunities by García, Silvia Valero, Briz, Eduardo López, Clérigues, Nieves Vila, Andrés, Jose Luis Poveda

    Published in Farmacia hospitalaria (01-03-2016)
    “…Occupational exposure to hazardous drugs can cause harmful effects on health professionals and several protective measures must be taken. Nevertheless,…”
    Get full text
    Journal Article
  18. 18

    Selective ophthalmic intra-arterial melphalan therapy for advanced retinoblastoma: Implementation and outcomes of a new chemotherapy protocol by García, Silvia Valero, Briz, Eduardo López, Cava, Paloma Escobar, Balaguer, Julia, Pelufo, Ana, Megías, Juan Eduardo, Andrés, Jose Luis Poveda

    Published in Journal of oncology pharmacy practice (01-06-2013)
    “…Retinoblastoma is a relatively uncommon childhood tumor. If untreated, RB grows to fill the eye and destroys the ocular globe’s internal architecture…”
    Get full text
    Journal Article
  19. 19

    Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19 by Palanques-Pastor, Tomás, López-Briz, Eduardo, Poveda Andrés, José Luis

    “…The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe…”
    Get full text
    Journal Article
  20. 20